Revenio Group Oyj


Revenio is a Finnish health tech group whose core business is tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy. The widely patented Icare product family is the current cornerstone of the Group’s success. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers.

On 4 December 2013, the Revenio Group purchased the majority of shares in Oscare Medical Oy. The company’s osteoporosis detection device helps in screening for osteoporosis, in diagnosing it, and in treatment follow-ups. This small, mobile device allows the cost-effective screening of large populations and reduces the incidence of minor and avoidable, osteoporosis-related fractures. Revenio sees Oscare Medical as a source of growth in its Health Technology segment. The device, which received CE approval in 2013, will be introduced to the market beginning in 2014.

The Revenio Group also includes other business operations, which are grouped under the Technology and Services segment. This segment’s operations have a shared global market and represent the cutting edge of technology products and services in their industry. These businesses are extremely profitable in their industries and generate positive cash flow.

In 2012, the Revenio Group’s turnover totaled 25.4 million euros, with its operating margin standing at 19.4%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.